Skip to Main Content


On April 12, 2024, The Wall Street Journal published an article on Zoetis reporting that health regulators in the U.S. and Europe have received thousands of complaints about Zoetis’s arthritis drugs, Librela (for dog) and Solensia (for cats), due to negative side effects. Additionally, the article reported that U.S. and Europe health regulators are conducting reviews of the drugs. 

Following this news, Zoetis’s stock price fell 8%, to close at $149.98 per share on April 12, 2024. 

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at  

Complete this form with your transactions in Zoetis Inc. securities between February 16, 2021 and April 11, 2024

Click Here to Print PDF of this Form

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Zoetis Inc. prior to the Class Period?
Are you a current or former employee of Zoetis Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email